Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...
Nat Clin Pract Endocrinol Metab. 2007;3(11):778-783. Clinical features initially attributed to PCOS Hirsutism, subfertility, greasy skin and acne Hirsutism, secondary amenorrhea, weight gain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback